Quick Answer
Barinthus Biotherapeutics plc. reported Diluted EPS of $1.64 per share (loss) for fiscal year 2025.
Barinthus Biotherapeutics plc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.64 | -5.8% |
| 2024 | -$1.55 | +18.8% |
| 2023 | -$1.91 | -1464.3% |
| 2022 | $0.14 | +107.1% |
| 2021 | -$1.96 | +12.5% |
| 2020 | -$2.24 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.36 | -71.4% | +30.8% |
| June 30, 2025 | -$0.52 | -20.9% | -6.1% |
| March 31, 2025 | -$0.49 | -22.5% | -133.3% |
| September 30, 2024 | -$0.21 | +43.2% | +51.2% |
| June 30, 2024 | -$0.43 | +30.6% | -7.5% |
| March 31, 2024 | -$0.40 | +16.7% | -8.1% |
| September 30, 2023 | -$0.37 | -268.2% | +40.3% |
| June 30, 2023 | -$0.62 | -251.2% | -29.2% |
- Barinthus Biotherapeutics plc. showed a decrease of -5.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Barinthus Biotherapeutics plc.’s diluted eps has grown by 26.8% (from $2.24 per share (loss) to $1.64 per share (loss)).
- The most recent figure is from Barinthus Biotherapeutics plc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: